On Monday, 7th July, shares of Metropolis Healthcare Ltd gained 2.35% to ₹1,815 on the NSE, rising ₹41.70 from the previous close of ₹1,773.30. The stock moved higher after the company shared its business update for the quarter ended June 30, 2025, highlighting robust growth across key segments.
According to the company’s regulatory filing dated 4th July, consolidated revenue grew approximately 23% year-on-year (YoY) in Q1FY26. This growth includes contributions from recently acquired entities — Core Diagnostics, Scientific Pathology, and Dr. Ahuja’s Pathology & Imaging Center. The integration of these acquisitions progressed as planned, with Core moving to a positive margin trajectory and the others outperforming company averages.
On a standalone basis (excluding acquisitions), revenues grew by around 13% YoY, driven by higher patient and test volumes, an improved product mix, and better realizations. Notably, the TruHealth Wellness segment recorded ~20% YoY growth, while the Specialty segment grew ~15% YoY during the quarter.
The company also reported improvements in EBITDA on a sequential basis owing to higher throughput, operational efficiencies, and operating leverage. Metropolis confirmed it remains debt-free, underscoring its strong financial position.
Management noted that the April–June period marked a return to normalized industry activity following a seasonal slowdown in Q4FY25. The company remains optimistic about sustained organic growth, particularly in high-end diagnostics and wellness services.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
